Clairity, Myriad Genetics, Inc. and MagView announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens. The agreement brings together three leaders in breast cancer: Clairity - developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman's five-year breast cancer risk directly from a routine mammogram; Myriad Genetics - a leader in molecular diagnostic testing and precision medicine, offering the MyRisk Hereditary Cancer Test with RiskScore, which combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk; MagView - a leader in comprehensive software solutions for breast imaging centers. For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad's MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView's Luminary Risk platform, which supports breast cancer risk assessment programs across the United States.
Headquartered in Fulton, Maryland, MagView's Luminary Risk software embeds into EHRs to enable breast centers to adopt a more personalized approach to breast cancer screening, focusing on patient experience and staff efficiency. MagView is utilized by more than 2,500 facilities across the U.S., including many of the nation's top cancer centers.
